An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.
BACKGROUND
An active haemovigilance programme was implemented to survey adverse events (AE) associated with transfusion of platelets photochemically treated with amotosalen and ultraviolet A (PCT-PLT). The results of 5106 transfusions have already been reported. Here we report the results of an additional 7437 PCT-PLT transfusions.


METHODS
The focus of this ongoing haemovigilance programme is to document all AEs associated with PCT-PLT transfusion. Data collected for AEs include: time of event after starting transfusion, clinical descriptions, vital signs, results from radiographs and bacterial cultures, event severity (Grade 0-4) and causal relationship to PCT-PLT transfusion.


RESULTS
One thousand four hundred patients (mean 60 years, range 1-96) received PCT-PLT transfusions. The majority of the patients (53.4%) had haematology-oncology diseases and required conventional chemotherapy (44.8%) or stem cell transplantation (8.6%). Sixty-eight PCT-PLT transfusions were associated with AE. Acute transfusion reactions (ATR), classified as an AE possibly related, probably related, or related to PCT-PLT transfusions were infrequent (n = 55, 55/7437 = 0.7%) and most were of Grade 1 severity. Thirty-nine patients (39/1400 = 2.8%) experienced one or more ATRs. The most frequently reported signs/symptoms were chills, fever, urticaria, dyspnoea, nausea and vomiting. Five AEs were considered severe (> or = Grade 2); however, no causal relationship to PCT-PLT transfusion was found. Repeated exposure to PCT-PLT did not increase the likelihood of an ATR. No cases of transfusion-related acute lung injury and no deaths due to PCT-PLT transfusions were reported.


CONCLUSIONS
Routine transfusion of PCT-PLT is well-tolerated in a wide range of patients. ATRs related to PCT-PLT transfusion were infrequent and most were of mild severity.
Osselaer
J C
JC
Blood Transfusion Center, Cliniques Universitaires de Mont Godinne, Universite Catholique de Louvain, Yvoir, Belgium.
Cazenave
J P
JP
Lambermont
M
M
Garraud
O
O
Hidajat
M
M
Barbolla
L
L
Tardivel
R
R
Defoin
L
L
Waller
C
C
Mendel
I
I
Raidot
J P
JP
Kandel
G
G
De Meuter
R
R
Fabrigli
P
P
Dehenau
D
D
Arroyo
J L
JL
Padrón
F
F
Gouezec
H
H
Corral
M
M
Jacquet
M
M
Sundin
D
D
Lin
L
L
Corash
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets; D001793:Blood Preservation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D005260:Female; D011564:Furocoumarins / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D017319:Photosensitizing Agents / Q000627:therapeutic use; D017713:Platelet Transfusion / Q000009:adverse effects*; D011446:Prospective Studies; D014466:Ultraviolet Rays
D011564:Furocoumarins; D017319:Photosensitizing Agents; C118577:amotosalen